From hormones to immunity: The physiology of immunology

Brain, Behavior, and Immunity

Volumn 18, Issue 2, 2004, Pages 95-113

  Kelley, Keith W ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

AIDS; Genetic x environment x disease interactions; Growth hormone; IGF I; IGF I resistance; Interleukin 1 ; Tumor necrosis factor

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOTROPIN; CYTOKINE; DEXAMETHASONE; GLUCOCORTICOID; GROWTH HORMONE; HORMONE; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 3; PLACEBO; SOMATOMEDIN C; T LYMPHOCYTE RECEPTOR; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOHYPOPHYSIS; ADRENAL CORTEX; AGING; ALZHEIMER DISEASE; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; BACILLUS ANTHRACIS; BIPOLAR DISORDER; CELL DEATH; CELL GROWTH; CELL LINEAGE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DNA EXTRACTION; DRUG MEGADOSE; DRUG TOXICITY; ENVIRONMENTAL FACTOR; EPITHELIUM CELL; GENETICS; HEMATOPOIETIC CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HUMAN GENOME; HYPOPHYSECTOMY; IMMUNITY; IMMUNIZATION; IMMUNOLOGY; IMMUNOMODULATION; MEMORY CELL; MENTAL DISEASE; MUSCLE ATROPHY; MUSCLE CELL; MYELOID PROGENITOR CELL; NERVE CELL; NUCLEOTIDE SEQUENCE; PATHOGENICITY; PHYSIOLOGY; PLAQUE FORMING CELL; POSTNATAL GROWTH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RODENT; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; SCHIZOPHRENIA; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STRESS; T LYMPHOCYTE; TH1 CELL; TH2 CELL; THYMUS ATROPHY;

EID: 0842287527     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2003.10.003     Document Type: Article

References (140)

1. Ballinger A.B., Azooz O., El-Haj T., Poole S., Farthing M.J. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut. 46:2000;694-700.
2. Barton E.R., Morris L., Musaro A., Rosenthal N., Sweeney H.L. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J. Cell Biol. 157:2002;137-148.
3. Belec L., Meillet D., Hernvann A., Gresenguet G., Gherardi R. Differential elevation of circulating interleukin-1β, tumor necrosis factor α, and interleukin-6 in AIDS-associated cachectic states. Clin. Diag. Lab. Immunol. 1:1994;117-120.
4. Besedovsky H.O., Sorkin E. Immunologic-neuroendocrine circuits: phyisological approaches. Ader R. Psychoneuroimmunology. 1981;545-574 Academic Press, New York.
5. Biesecker, B.B., Peay, H.L., 2003. Ethical issues in psychiatric genetics research: points to consider. Psychopharmacology (Berl).
6. Bjerknes R., Aarskog D. Priming of human polymorphonuclear neutrophilic leukocytes by insulin-like growth factor I: increased phagocytic capacity, complement receptor expression, degranulation, and oxidative burst. J. Clin. Endocrinol. Metab. 80:1995;1948-1955.
7. Bjerknes R., Vesterhus P., Aarskog D. Increased neutrophil insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced functional capacity in patients with untreated Laron syndrome. Eur. J. Endocrinol. 136:1997;92-95.
8. Blalock J.E. The immune system as a sensory organ. J. Immunol. 132:1984;1067-1070.
9. Blecha F., Barry R.A., Kelley K.W. Stress-induced alterations in delayed-type hypersensitivity to SRBC and contact sensitivity to DNFB in mice. Proc. Soc. Exp. Biol. Med. 169:1982;239-246.
10. Blecha F., Kelley K.W., Satterlee D.G. Adrenal involvement in the expression of delayed-type hypersensitivity to SRBC and contact sensitivity to DNFB in stressed mice. Proc. Soc. Exp. Biol. Med. 169:1982;247-252.
11. Blethen S.L., Allen D.B., Graves D., August G., Moshang T., Rosenfeld R. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J. Clin. Endocrinol. Metab. 81:1996;1704-1710.
12. Broussard S.R., McCusker R.H., Novakofski J.E., Strle K., Shen W.H., Johnson R.W., Freund G.G., Dantzer R., Kelley K.W. Cytokine-hormone interactions: tumor necrosis factor alpha impairs biologic activity and downstream activation signals of the insulin-like growth factor I receptor in myoblasts. Endocrinology. 144:2003;2988-2996.
13. Burgess W., Liu Q., Zhou J., Tang Q., Ozawa A., VanHoy R., Arkins S., Dantzer R., Kelley K.W. The immune-endocrine loop during aging: role of growth hormone and insulin-like growth factor-I. Neuroimmunomodulation. 6:1999;56-68.
14. Burgess W., Jesse K., Tang Q., Broussard S.R., Dantzer R., Kelley K.W. Insulin-like growth factor-I and the cytokines IL-3 and IL-4 promote survival of progenitor myeloid cells by different mechanisms. J. Neuroimmunol. 135:2003;82-90.
15. Cabib S., Orsini C., Le Moal M., Piazza P.V. Abolition and reversal of strain differences in behavioral responses to drugs of abuse after a brief experience. Science. 289:2000;463-465.
16. Capuron L., Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav. Immun. 17(Suppl. 1):2003;S119-S124.
17. Carro E., Trejo J.L., Gomez-Isla T., LeRoith D., Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 8:2002;1390-1397.
18. Carro E., Trejo J.L., Nunez A., Torres-Aleman I. Brain repair and neuroprotection by serum insulin-like growth factor I. Mol. Neurobiol. 27:2003;153-162.
19. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithwaite A., Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 301:2003;386-389.
20. Chesler E.J., Wilson S.G., Lariviere W.R., Rodriguez-Zas S.L., Mogil J.S. Identification and ranking of genetic and laboratory environment factors influencing a behavioral trait, thermal nociception, via computational analysis of a large data archive. Neurosci. Biobehav. Rev. 26:2002;907-923.
21. Cittadini A., Ines Comi L., Longobardi S., Rocco Petretta V., Casaburi C., Passamano L., Merola B., Durante-Mangoni E., Sacca L., Politano L. A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular dystrophies. Eur. Heart J. 24:2003;664-672.
22. Cleeland C.S., Bennett G.J., Dantzer R., Dougherty P.M., Dunn A.J., Meyers C.A., Miller A.H., Payne R., Reuben J.M., Wang X.S., Lee B.N. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 97:2003;2919-2925.
23. Dantzer R., Baldwin B.A. Changes in heart rate during suppression of operant responding in pigs. Physiol. Behav. 12:1974;385-391.
24. Dantzer R., Mormede P., Favre B. Fear-dependent variations in continuous avoidance behavior of pigs. II. Effects of diazepam on acquisition and performance of Pavlovian fear conditioning and plasma corticosteroid levels. Psychopharmacology (Berl.). 49:1976;75-78.
25. Dantzer R., Arnone M., Mormede P. Effects of frustration on behaviour and plasma corticosteroid levels in pigs. Physiol. Behav. 24:1980;1-4.
26. Dantzer R., Kelley K.W. Stress and immunity: an integrated view of relationships between the brain and the immune system. Life Sci. 44:1989;1995-2008.
27. Dantzer R., Gheusi G., Johnson R.W., Kelley K.W. Central administration of insulin-like growth factor-1 inhibits lipopolysaccharide-induced sickness behavior in mice. NeuroReport. 10:1999;289-292.
28. Dantzer R., Wollman E.E., Yirmiya R. Cytokines and depression: an update. Brain Behav. Immun. 16:2002;501-502.
29. Dantzer R. Innate immunity at the forefront of psychoneuroimmunology. Brain Behav. Immun. 18:2004;1-6.
30. De Benedetti F., Alonzi T., Moretta A., Lazzaro D., Costa P., Poli V., Martini A., Ciliberto G., Fattori E. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J. Clin. Invest. 99:1997;643-650.
31. De Luca A., Pierno S., Liantonio A., Cetrone M., Camerino C., Fraysse B., Mirabella M., Servidei S., Ruegg U.T., Conte Camerino D. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J. Pharmacol. Exp. Ther. 304:2003;453-463.
32. Dhabhar F.S. Stress-induced augmentation of immune function - the role of stress hormones, leukocyte trafficking, and cytokines. Brain Behav. Immun. 16:2002;785-798.
33. Dobashi H., Sato M., Tanaka T., Tokuda M., Ishida T. Growth hormone restores glucocorticoid-induced T cell suppression. FASEB J. 15:2001;1861-1863.
34. Dubos, R., 1973. Les microbes et le terrain. http://agora.qc.ca/reftext. nsf/Documents/Louis_Pasteur-Les_microbes_et_le_terrain_par_Rene_Dubos.
35. Edwards 3rd C.K., Ghiasuddin S.M., Schepper J.M., Yunger L.M., Kelley K.W. A newly defined property of somatotropin: priming of macrophages for production of superoxide anion. Science. 239:1988;769-771.
36. Edwards 3rd C.K., Yunger L.M., Lorence R.M., Dantzer R., Kelley K.W. The pituitary gland is required for protection against lethal effects of Salmonella typhimurium. Proc. Natl. Acad. Sci. USA. 88:1991;2274-2277.
37. Edwards 3rd C.K., Arkins S., Yunger L.M., Blum A., Dantzer R., Kelley K.W. The macrophage-activating properties of growth hormone. Cell. Mol. Neurobiol. 12:1992;499-510.
38. Edwards 3rd C.K., Ghiasuddin S.M., Yunger L.M., Lorence R.M., Arkins S., Dantzer R., Kelley K.W. In vivo administration of recombinant growth hormone or gamma interferon activities macrophages: enhanced resistance to experimental Salmonella typhimurium infection is correlated with generation of reactive oxygen intermediates. Infect. Immun. 60:1992;2514-2521.
39. Ellaurie M., Rubinstein A. Elevated tumor necrosis factor-α in association with severe anemia in human immunodeficiency virus infection and Mycobacterium avium intracellulare infection. Pediatr. Hematol. Oncol. 12:1995;221-230.
40. Ellis K.J., Lee P.D., Pivarnik J.M., Bukar J.G., Gesundheit N. Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor I and growth hormone. J. Clin. Endocrinol. Metab. 81:1996;3033-3038.
41. Engvall E., Wewer U.M. The new frontier in muscular dystrophy research: booster genes. FASEB J. 17:2003;1579-1584.
42. FDA, 1995. Treatment IND for AIDS-related wasting authorized. J. Am. Med. Assoc. 273, 982.
43. Flint J. Analysis of quantitative trait loci that influence animal behavior. J. Neurobiol. 54:2003;46-77.
44. French R.A., Zachary J.F., Dantzer R., Frawley L.S., Chizzonite R., Parnet P., Kelley K.W. Dual expression of p80 type I and p68 type II interleukin-I receptors on anterior pituitary cells synthesizing growth hormone. Endocrinology. 137:1996;4027-4036.
45. French R.A., Broussard S.R., Meier W.A., Minshall C., Arkins S., Zachary J.F., Dantzer R., Kelley K.W. Age-associated loss of bone marrow hematopoietic cells is reversed by GH and accompanies thymic reconstitution. Endocrinology. 143:2002;690-699.
46. Fu Y.K., Arkins S., Wang B.S., Kelley K.W. A novel role of growth hormone and insulin-like growth factor-I. Priming neutrophils for superoxide anion secretion. J. Immunol. 146:1991;1602-1608.
47. Fu Y.K., Arkins S., Fuh G., Cunningham B.C., Wells J.A., Fong S., Cronin M.J., Dantzer R., Kelley K.W. Growth hormone augments superoxide anion secretion of human neutrophils by binding to the prolactin receptor. J. Clin. Invest. 89:1992;451-457.
48. Fu Y.K., Arkins S., Li Y.M., Dantzer R., Kelley K.W. Reduction in superoxide anion secretion and bactericidal activity of neutrophils from aged rats: reversal by the combination of gamma interferon and growth hormone. Infect. Immun. 62:1994;1-8.
49. Garlick P.J., McNurlan M.A., Bark T., Lang C.H., Gelato M.C. Hormonal regulation of protein metabolism in relation to nutrition and disease. J. Nutr. 128:1998;356S-359S.
50. Geffner M.E., Yeh D.Y., Landaw E.M., Scott M.L., Stiehm E.R., Bryson Y.J., Israele V. In vitro insulin-like growth factor-I, growth hormone, and insulin resistance occurs in symptomatic human immunodeficiency virus-1-infected children. Pediatr. Res. 34:1993;66-72.
51. Gisler R.H., Schenkel-Hulliger L. Hormonal regulation of the immune response. II. Influence of pituitary and adrenal activity on immune responsiveness in vitro. Cell. Immunol. 2:1971;646-657.
52. Gisler R.H., Bussard A.E., Mazie J.C., Hess R. Hormonal regulation of the immune response. I. Induction of an immune response in vitro with lymphoid cells from mice exposed to acute systemic stress. Cell. Immunol. 2:1971;634-645.
53. Gregorevic P., Plant D.R., Leeding K.S., Bach L.A., Lynch G.S. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. Am. J. Pathol. 161:2002;2263-2272.
54. Grinspoon S., Mulligan K. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 36:2003;S69-S78.
55. Heffner K.L., Loving T.J., Robles T.F., Kiecolt-Glaser J.K. Examining psychosocial factors related to cancer incidence and progression: in search of the silver lining. Brain Behav. Immun. 17(Suppl. 1):2003;S109-S111.
56. Hettema J.M., Neale M.C., Kendler K.S. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am. J. Psychiatry. 158:2001;1568-1578.
57. Inoue K., Lupski J.R. Genetics and genomics of behavioral and psychiatric disorders. Curr. Opin. Genet. Dev. 13:2003;303-309.
58. Inoue T., Saito H., Matsuda T., Fukatsu K., Han I., Furukawa S., Ikeda S., Muto T. Growth hormone and insulin-like growth factor I augment bactericidal capacity of human polymorphonuclear neutrophils. Shock. 10:1998;278-284.
59. Inoue T., Saito H., Tsuno N., Fukatsu K., Lin M.T., Inaba T., Han I., Furukawa S., Ikeda S., Matsuda T., Muto T. Effects of growth hormone and insulin-like growth factor I on opsonin receptor expression on local and systemic phagocytes in a lethal peritonitis model. Crit. Care Med. 26:1998;338-343.
60. Jain S., Golde D.W., Bailey R., Geffner M.E. Insulin-like growth factor-I resistance. Endocr. Rev. 19:1998;625-646.
61. Jones J. From Here to Eternity. 1951;Dell Publishing, Random House, Inc. New York.
62. Kaspar B.K., Llado J., Sherkat N., Rothstein J.D., Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 301:2003;839-842.
63. Kelley K.W. Stress and immune function: a bibliographic review. Ann. Rech. Vet. 141:1980;445-478.
64. Kelley, K.W., 1985. Immunological consequences of changing environmental stimuli. In: Moberg, G.P. (Ed.), Animal Stress. American Physiological Society, Bethesda, MD, pp. 193-233.
65. 3 pituitary adenoma cells can reverse thymic aging in rats. Proc. Natl. Acad. Sci. USA. 83:1986;5663-5667.
66. Kelley K.W. Cross-talk between the immune and endocrine systems. J. Anim. Sci. 66:1988;2095-2108.
67. Kelley K.W. Growth hormone, lymphocytes and macrophages. Biochem. Pharmacol. 38:1989;705-713.
68. Kelley K.W., Bluthe R.M., Dantzer R., Zhou J.H., Shen W.H., Johnson R.W., Broussard S.R. Cytokine-induced sickness behavior. Brain Behav. Immun. 17(Suppl 1):2003;S112-S118.
69. Kelley K.W., Dantzer R. Growth hormone and prolactin as natural antagonists of glucocorticoids in immunoregulation. Plotnikoff N., Faith A.M.R., Wybran J. Stress and Immunity. 1991;433-452 CRC Press, Boca Raton.
70. Kelley K.W., Johnson R.W., Dantzer R. Immunology discovers physiology. Vet. Immunol. Immunopathol. 43:1994;157-165.
71. Kelley K.W., Arkins S., Li Y.M. Growth hormone, prolactin and insulin like growth factor: new jobs for old players. Brain Behav. Immun. 6:1992;317-326.
72. Kent S., Bluthe R.M., Dantzer R., Hardwick A.J., Kelley K.W., Rothwell N.J., Vannice J.L. Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1. Proc. Natl. Acad. Sci. USA. 89:1992;9117-9120.
73. Kent S., Bluthe R.M., Kelley K.W., Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol. Sci. 13:1992;24-28.
74. Kent S., Bret-Dibat J.L., Kelley K.W., Dantzer R. Mechanisms of sickness-induced decreases in food-motivated behavior. Neurosci. Biobehav. Rev. 20:1996;171-175.
75. Konsman J.P., Parnet P., Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci. 25:2002;154-159.
76. Koo G.C., Huang C., Camacho R., Trainor C., Blake J.T., Sirotina-Meisher A., Schleim K.D., Wu T.J., Cheng K., Nargund R., McKissick G. Immune enhancing effect of a growth hormone secretagogue. J. Immunol. 166:2001;4195-4201.
77. Koo J.W., Park C.H., Choi S.H., Kim N.J., Kim H.S., Choe J.C., Suh Y.H. The postnatal environment can counteract prenatal effects on cognitive ability, cell proliferation, and synaptic protein expression. FASEB J. 17:2003;1556-1558.
78. Krentz A.J., Koster F.T., Crist D.M., Finn K., Johnson L.Z., Boyle P.J., Schade D.S. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J. Acquir. Immune Defic. Syndr. 6:1993;245-251.
79. Kumar M., Kumar A.M., Waldrop D., Antoni M.H., Eisdorfer C. HIV-1 infection and its impact on the HPA axis, cytokines, and cognition. Stress. 6:2003;167-172.
80. Lawn S.D., Shattock R.J., Acheampong J.W., Lal R.B., Folks T.M., Griffin G.E., Butera S.T. Sustained plasma TNF-α and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans. AIDS. 13:1999;2231-2237.
81. Lazarus D.D., Moldawer L.L., Lowry S.F. Insulin-like growth factor-1 activity is inhibited by interleukin-1. α , tumor necrosis factor- α , and interleukin-6 Lymphokine Cytokine Res. 12:1993;219-223.
82. Ledru E., Christeff N., Patey O., de Truchis P., Melchior J.C., Gougeon M.L. Alteration of tumor necrosis factor-α T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood. 95:2000;3191-3198.
83. Lee P.D., Pivarnik J.M., Bukar J.G., Muurahainen N., Berry P.S., Skolnik P.R., Nerad J.L., Kudsk K.A., Jackson L., Ellis K.J., Gesundheit N. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J. Clin. Endocrinol. Metab. 81:1996;2968-2975.
84. Li Y.M., Arkins S., McCusker R.H. Jr., Donovan S.M., Liu Q., Jayaraman S., Dantzer R., Kelley K.W. Macrophages synthesize and secrete a 25-kilodalton protein that binds insulin-like growth factor-I. J. Immunol. 156:1996;64-72.
85. Li Y.M., Schacher D.H., Liu Q., Arkins S., Rebeiz N., McCusker R.H. Jr., Dantzer R., Kelley K.W. Regulation of myeloid growth and differentiation by the insulin-like growth factor I receptor. Endocrinology. 138:1997;362-368.
86. Lieberman S.A., Butterfield G.E., Harrison D., Hoffman A.R. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 78:1994;404-410.
87. Lieskovska J., Guo D., Derman E. IL-6-overexpression brings about growth impairment potentially through a GH receptor defect. Growth Horm. IGF Res. 12:2002;388-398.
88. ′ -kinase by insulin-like growth factor-I rescues promyeloid cells from apoptosis and permits their differentiation into granulocytes J. Immunol. 159:1997;829-837.
89. ′ -kinase and promotion of macrophage differentiation by insulin-like growth factor-I J. Immunol. 160:1998;1393-1401.
90. Liu Q., VanHoy R.W., Zhou J.H., Dantzer R., Freund G.G., Kelley K.W. Elevated cyclin E levels, inactive retinoblastoma protein, and suppression of the p27(KIP1) inhibitor characterize early development of promyeloid cells into macrophages. Mol. Cell. Biol. 19:1999;6229-6239.
91. Lupu F., Terwilliger J.D., Lee K., Segre G.V., Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev. Biol. 229:2001;141-162.
92. MacArthur R.D., Lederman M.M., Benson C.A., Chernoff M.C., MacGregor R.R., Spritzler J., Mahon L.F., Yen-Lieberman B., Purvis S. Effects of Mycobacterium avium complex-infection treatment on cytokine expression in human immunodeficiency virus-infected persons: results of AIDS clinical trials group protocol 853. J. Infect. Dis. 181:2000;1486-1490.
93. Maneatis T., Baptista J., Connelly K., Blethen S. Growth hormone safety update from the National Cooperative Growth Study. J. Pediatr. Endocrinol. Metab. 13(Suppl. 2):2000;1035-1044.
94. Mantzoros C.S., Moses A.C. Whither recombinant human growth hormone? Ann. Intern. Med. 125:1996;932-934.
95. Mason J.L., Xuan S., Dragatsis I., Efstratiadis A., Goldman J.E. Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination. J. Neurosci. 23:2003;7710-7718.
96. Mason J.W. A review of psychoendocrine research on the pituitary-adrenal cortical system. Psychosom. Med. 30(Suppl.):1968;576-607.
97. Matsuda T., Saito H., Inoue T., Fukatsu K., Han I., Furukawa S., Ikeda S., Muto T. Growth hormone inhibits apoptosis and up-regulates reactive oxygen intermediates production by human polymorphonuclear neutrophils. J. Parenter. Enteral. Nutr. 22:1998;368-374.
98. McNurlan M.A., Garlick P.J., Steigbigel R.T., DeCristofaro K.A., Frost R.A., Lang C.H., Johnson R.W., Santasier A.M., Cabahug C.J., Fuhrer J., Gelato M.C. Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease. J. Clin. Invest. 100:1997;2125-2132.
99. Miller A.H. Cytokines and sickness behavior: implications for cancer care and control. Brain Behav. Immun. 17(Suppl. 1):2003;S132-S134.
100. ′ -kinase to protect hemopoietic progenitors against apoptosis depends upon the extracellular survival factor J. Immunol. 156:1996;939-947.
101. ′ -kinase, but not S6-kinase, is required for insulin-like growth factor-I and IL-4 to maintain expression of Bcl-2 and promote survival of myeloid progenitors J. Immunol. 162:1999;4542-4549.
102. Moldin S.O. NIMH Human Genetics Initiative: 2003 update. Am. J. Psychiatry. 160:2003;621-622.
103. Moore R.D. Anemia and human immunodeficiency virus disease in the era of highly active antiretroviral therapy. Semin. Hematol. 37:2000;18-23.
104. Mulligan K., Grunfeld C., Hellerstein M.K., Neese R.A., Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J. Clin. Endocrinol. Metab. 77:1993;956-962.
105. Mulligan K., Tai V.W., Schambelan M. Use of growth hormone and other anabolic agents in AIDS wasting. J. Parenter. Enteral. Nutr. 23:1999;S202-S209.
106. Murphy W.J., Longo D.L. Growth hormone as an immunomodulating therapeutic agent. Immunol. Today. 21:2000;211-213.
107. Mynarcik D.C., Frost R.A., Lang C.H., DeCristofaro K., McNurlan M.A., Garlick P.J., Steigbigel R.T., Fuhrer J., Ahnn S., Gelato M.C. Insulin-like growth factor system in patients with HIV infection: effect of exogenous growth hormone administration. J. Acquir. Immune Defic. Syndr. 22:1999;49-55.
108. Nicol L. L'épopée pastorienne et la médecine vétérinaire. 1974;Nicol, Garches, France.
109. Odeh M. The role of tumour necrosis factor-. α in acquired immunodeficiency syndrome J. Intern. Med. 228:1990;549-556.
110. Paton N.I., Newton P.J., Sharpstone D.R., Ross H.M., Cotton J., Calder A.G., Milne E., Elia M., Shah S., Engrand P., Macallan D.C., Gazzard B.G., Griffin G.E. Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. AIDS. 13:1999;1195-1202.
111. Previte J.J., Berry L.J. The effect of environmental temperature on the host-parasite relationship in mice. J. Infect. Dis. 119:1962;201-209.
112. Pugh R.C., Fleshner M., Watkins L.R., Maier S.F., Rudy J.W. The immune system and memory consolidation: a role for the cytokine IL-1β Neurosci. Biobehav. Rev. 25:2001;29-41.
113. Raison C.L., Miller A.H. Depression in cancer: new developments regarding diagnosis and treatment. Biol. Psychiatry. 54:2003;283-294.
114. Rosenkranz M.A., Jackson D.C., Dalton K.M., Dolski I., Ryff C.D., Singer B.H., Muller D., Kalin N.H., Davidson R.J. Affective style and in vivo immune response: neurobehavioral mechanisms. Proc. Natl. Acad. Sci. USA. 100:2003;11148-11152.
115. Sandoval C., Stojanova A., DiFalco M.R., Congote L.F. The fusion of IGF I with stromal cell-derived factor I or alpha1 proteinase inhibitor alters their mitogenic or chemotactic activities while keeping their ability to inhibit HIV-1-gp120 binding. Biochem. Pharmacol. 65:2003;2055-2063.
116. Savino W., Smaniotto S., Binart N., Postel-Vinay M.C., Dardenne M. In vivo effects of growth hormone on thymic cells. Ann. N. Y. Acad. Sci. 992:2003;179-185.
117. Schacher D.H., VanHoy R.W., Liu Q., Arkins S., Dantzer R., Freund G.G., Kelley K.W. Developmental expression of insulin receptor substrate-2 during dimethylsulfoxide-induced differentiation of human HL-60 cells. J. Immunol. 164:2000;113-120.
118. Schambelan M., Mulligan K., Grunfeld C., Daar E.S., LaMarca A., Kotler D.P., Wang J., Bozzette S.A., Breitmeyer J.B. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial Serostim Study Group. Ann. Intern. Med. 125:1996;873-882.
119. Schwartlander B., Stover J., Walker N., Bollinger L., Gutierrez J.P., McGreevey W., Opuni M., Forsythe S., Kumaranayake L., Watts C., Bertozzi S. AIDS. Resource needs for HIV/AIDS. Science. 292:2001;2434-2436.
120. Selye H. A syndrome produced by diverse nocuous agents. Nature. 138:1936;38.
121. Selye H. Stress in Health and Disease. 1976;Butterworths, Boston.
122. Shen W.H., Zhou J.H., Broussard S.R., Freund G.G., Dantzer R., Kelley K.W. Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor. Cancer Res. 62:2002;4746-4756.
123. Shen, W.H., Yin, Y., Broussard, S.R., McCusker, R.H., Freund, G.G., Dantzer, R., Kelley, K.W., 2004. TNFα inhibits cyclin A expression and RB hyperphosphorylation triggered by IGF-I induction of new E2F-1 synthesis. Journal of Biological Chemistry. Published online on December 16, 2003. doi:10.1074/jbc.M310264200 (scheduled for print publication in March, 2004).
124. Steele F.R. Growth hormone and AIDS-related wasting. Nat. Med. 2:1996;369-370.
125. Takagi K., Suzuki F., Barrow R.E., Wolf S.E., Kobayashi M., Herndon D.N. Growth hormone improves immune function and survival in burned mice infected with herpes simplex virus type 1. J. Surg. Res. 69:1997;166-170.
126. Takagi K., Suzuki F., Barrow R.E., Wolf S.E., Kobayashi M., Herndon D.N. Growth hormone improves the resistance of thermally injured mice infected with herpes simplex virus type 1. J. Trauma. 44:1998;517-522.
127. Tracey K.J. The inflammatory reflex. Nature. 420:2002;853-859.
128. Ursin H. The psychology in psychoneuroendocrinology. Psychoneuroendocrinology. 23:1998;555-570.
129. Van Loon K. Safety of high doses of recombinant human growth hormone. Horm. Res. 49:1998;78-81.
130. Venters H.D., Tang Q., Liu Q., VanHoy R.W., Dantzer R., Kelley K.W. A new mechanism of neurodegeneration: a proinflammatory cytokine inhibits receptor signaling by a survival peptide. Proc. Natl. Acad. Sci. USA. 96:1999;9879-9884.
131. Venters H.D., Dantzer R., Freund G.G., Broussard S.R., Kelley K.W. Growth hormone and insulin-like growth factor as cytokines in the immune system. Ader R., Felton D., Cohen N. Psychoneuroimmunology. third ed. 2001;339-362 Academic Press, New York.
132. Vincent A.M., Feldman E.L. Control of cell survival by IGF signaling pathways. Growth Horm. IGF Res. 12:2002;193-197.
133. Wanke C.A., Silva M., Knox T.A., Forrester J., Speigelman D., Gorbach S.L. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 31:2000;803-805.
134. Warwick-Davies J., Lowrie D.B., Cole P.J. Growth hormone activation of human monocytes for superoxide production but not tumor necrosis factor production, cell adherence, or action against Mycobacterium tuberculosis. Infect. Immun. 63:1995;4312-4316.
135. 2. J. Immunol. 154:1995;1909-1918.
136. Waters D., Danska J., Hardy K., Koster F., Qualls C., Nickell D., Nightingale S., Gesundheit N., Watson D., Schade D. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double- blind, placebo-controlled trial. Ann. Intern. Med. 125:1996;865-872.
137. Watkins L.R., Maier S.F. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol. Rev. 82:2002;981-1011.
138. Welniak L.A., Tian Z.G., Sun R., Keller J.R., Richards S., Ruscetti F.W., Murphy W.J. Effects of growth hormone and prolactin on hematopoiesis. Leuk. Lymphoma. 38:2000;435-445.
139. Woods J.A., Ceddia M.A., Zack M.D., Lowder T.W., Lu Q. Exercise training increases the naive to memory T cell ratio in old mice. Brain Behav. Immun. 17:2003;384-392.
140. Woody M.A., Welniak L.A., Richards S., Taub D.D., Tian Z., Sun R., Longo D.L., Murphy W.J. Use of neuroendocrine hormones to promote reconstitution after bone marrow transplantation. Neuroimmunomodulation. 6:1999;69-80.